A phase II/III study of camrelizumab plus apatinib as perioperative treatment of resectable hepatocellular carcinoma at intermediate-high risk of recurrence: Primary results of major pathologic response from phase II stage

被引：0
|
作者：
Zhou, Jian
Fan, Jia
Gu, Fang-Ming
Li, Tao
Bai, Dou-Sheng
Sun, Hui-Chuan
Wang, Zheng
Qiu, Shuang-Jian
Ye, Qing-Hai
Shi, Ying-Hong
Gao, Qiang
Wang, Xiao-Ying
Yang, Xin-Rong
Shi, Guo-Ming
Peng, Yuan-Fei
机构：
[1] Fudan Univ, Zhongshan Hosp, Liver Canc Inst, Minist Educ, Shanghai, Peoples R China
[2] Fudan Univ, Minist Educ, Key Lab Carcinogenesis & Canc Invas, Shanghai, Peoples R China
[3] Naval Med Univ, Affiliated Hosp 3, Eastern Hepatobiliary Surg Hosp, Shanghai, Peoples R China
[4] Shandong Univ, Qilu Hosp, Jinan, Peoples R China
[5] Yangzhou Univ, Subei Peoples Hosp, Yangzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4126
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Updated results of the phase II ALTER-H004: Anlotinib combined with TACE as adjuvant therapy in hepatocellular carcinoma patients at high risk of recurrence after surgery
    Wu, Zheng
    Wang, Zheng
    Zhang, Lei
    Song, Xiaojing
    Du, Xilin
    Tan, Kai
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [42] Perioperative Adriamycin plus ifosfamide vs. gemcitabine plus docetaxel for high-risk soft tissue sarcomas: randomised, phase II/III study JCOG1306
    Kazuhiro Tanaka
    Ryunosuke Machida
    Akira Kawai
    Robert Nakayama
    Satoshi Tsukushi
    Kunihiro Asanuma
    Yoshihiro Matsumoto
    Hiroaki Hiraga
    Koji Hiraoka
    Munenori Watanuki
    Tsukasa Yonemoto
    Satoshi Abe
    Hirohisa Katagiri
    Yoshihiro Nishida
    Akihito Nagano
    Yoshiyuki Suehara
    Hiroyuki Kawashima
    Masanori Kawano
    Takeshi Morii
    Hiroshi Hatano
    Junya Toguchida
    Tomotake Okuma
    Masanobu Takeyama
    Satoshi Takenaka
    Toshihiro Akisue
    Taisuke Furuta
    Makoto Emori
    Toru Hiruma
    Hidetatsu Outani
    Tetsuji Yamamoto
    Tomoko Kataoka
    Haruhiko Fukuda
    Toshifumi Ozaki
    Yukihide Iwamoto
    British Journal of Cancer, 2022, 127 : 1487 - 1496
  • [43] Perioperative Adriamycin plus ifosfamide vs. gemcitabine plus docetaxel for high-risk soft tissue sarcomas: randomised, phase II/III study JCOG1306
    Tanaka, Kazuhiro
    Machida, Ryunosuke
    Kawai, Akira
    Nakayama, Robert
    Tsukushi, Satoshi
    Asanuma, Kunihiro
    Matsumoto, Yoshihiro
    Hiraga, Hiroaki
    Hiraoka, Koji
    Watanuki, Munenori
    Yonemoto, Tsukasa
    Abe, Satoshi
    Katagiri, Hirohisa
    Nishida, Yoshihiro
    Nagano, Akihito
    Suehara, Yoshiyuki
    Kawashima, Hiroyuki
    Kawano, Masanori
    Morii, Takeshi
    Hatano, Hiroshi
    Toguchida, Junya
    Okuma, Tomotake
    Takeyama, Masanobu
    Takenaka, Satoshi
    Akisue, Toshihiro
    Furuta, Taisuke
    Emori, Makoto
    Hiruma, Toru
    Outani, Hidetatsu
    Yamamoto, Tetsuji
    Kataoka, Tomoko
    Fukuda, Haruhiko
    Ozaki, Toshifumi
    Iwamoto, Yukihide
    BRITISH JOURNAL OF CANCER, 2022, 127 (08) : 1487 - 1496
  • [44] A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY Tract Cancers (BTC) at high risk for recurrence: PURITY study
    Niger, Monica
    Nichetti, Federico
    Fornaro, Lorenzo
    Pircher, Chiara
    Morano, Federica
    Palermo, Federica
    Rimassa, Lorenza
    Pressiani, Tiziana
    Berardi, Rossana
    Gardini, Andrea Casadei
    Sperti, Elisa
    Salvatore, Lisa
    Melisi, Davide
    Bergamo, Francesca
    Siena, Salvatore
    Mosconi, Stefania
    Longarini, Raffaella
    Arcangeli, Giuseppina
    Corallo, Salvatore
    Delliponti, Laura
    Tamberi, Stefano
    Fea, Elena
    Brandi, Giovanni
    Rapposelli, Ilario Giovanni
    Salati, Massimiliano
    Baili, Paolo
    Miceli, Rosalba
    Ljevar, Silva
    Cavallo, Ilaria
    Sottotetti, Elisa
    Martinetti, Antonia
    Busset, Michele Droz Dit
    Sposito, Carlo
    Di Bartolomeo, Maria
    Pietrantonio, Filippo
    de Braud, Filippo
    Mazzaferro, Vincenzo
    BMC CANCER, 2024, 24 (01)
  • [45] Perioperative FOLFOX 4 Versus FOLFOX 4 Plus Cetuximab Versus Immediate Surgery for High-Risk Stage II and III Colon Cancers A Phase II Multicenter Randomized Controlled Trial (PRODIGE 22)
    Karoui, M.
    Rullier, A.
    Piessen, G.
    Legoux, J. L.
    Barbier, E.
    De Chaisemartin, C.
    Lecaille, C.
    Bouche, O.
    Ammarguellat, H.
    Brunetti, F.
    Prudhomme, M.
    Regimbeau, J. M.
    Glehen, O.
    Lievre, A.
    Portier, G.
    Hartwig, J.
    Goujon, G.
    Romain, B.
    Lepage, C.
    Taieb, J.
    ANNALS OF SURGERY, 2020, 271 (04) : 637 - 645
  • [46] Updated results of ALTER-H006: A phase II study of benmelstobart (PD-L1 inhibitor) plus anlotinib as adjuvant therapy in hepatocellular carcinoma (HCC) with high risk of recurrence after radical resection.
    Duan, Xiaohui
    Wu, Dongde
    Zhou, Cuncai
    Tian, Yifeng
    Shen, Jian
    Xu, Guohui
    Bai, Yannan
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 601 - 601
  • [47] Preliminary results of the phase II ALTER-H004: Anlotinib combined with TACE as adjuvant therapy in hepatocellular carcinoma patients at high risk of post surgery recurrence.
    Wu, Zheng
    Wang, Zheng
    Zhang, Lei
    Song, Xiaojing
    Du, Xilin
    Tan, Kai
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [48] Camrelizumab plus apatinib as maintenance treatment in patients with extensive-stage small cell lung cancer who were responding or stable after standard first-line chemotherapy (CAMERA): Results from a single-arm, phase II trial
    Wang, Q. M.
    Wu, Y.
    Wang, Q.
    Ma, S.
    Lu, H.
    Liu, Y.
    ANNALS OF ONCOLOGY, 2023, 34 : S1674 - S1674
  • [49] 5-fluorouracil plus high dose levofolinic acid and oral hydroxyurea for the treatment of primary hepatocellular carcinomas: Results of a phase II multicenter study of the southern Italy Oncology Group (GOIM)
    Gebbia, V
    Maiello, E
    Serravezza, G
    Giotta, F
    Testa, A
    Borsellino, N
    Pezzella, G
    Colucci, G
    ANTICANCER RESEARCH, 1999, 19 (2B) : 1407 - 1410
  • [50] ALTER-H-004: A phase II study of anlotinib combined with TACE as adjuvant therapy in hepatocellular carcinoma patients at high risk of post-surgery recurrence
    Wu, Z.
    Wang, Z.
    Du, X.
    Zhang, L.
    ANNALS OF ONCOLOGY, 2020, 31 : S703 - S703
12345